Compare Strategy Inc. (MSTR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Zoetis Inc — how do they compare? Strategy Inc. trades at $102.09 (market cap $35.47B), while Zoetis Inc trades at $75.53 (market cap $31.95B). The key difference: Strategy Inc. and Zoetis Inc are close in size by market cap, and Zoetis Inc pays a 2.78% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals.
| MSTR | ZTS | |
|---|---|---|
Market Cap | $35.47B | $31.95B |
Sector | Technology | Health |
52-Week High | $426.40 | $156.76 |
52-Week Low | $82.31 | $71.91 |
Enterprise Value | $50.50B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $101.95, up 7.49% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of -$38.25, missing expectations, while Q3 2025 showed a positive surprise. Revenue remains stable near $477M, but net income margin is deeply negative at -806.35%. Recent news highlights institutional stake adjustments and strategic Bitcoin-related capital moves, influencing investor sentiment.
Outlook is mixed: analyst consensus targets $237.63 with 62% buy ratings, suggesting significant upside, but high valuation multiples and persistent losses pose risks. Key opportunities include potential Bitcoin adoption benefits, while risks involve earnings volatility and debt levels. Investors should weigh strong analyst optimism against fundamental challenges.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
